Success Stories: NAILG Secures Swift EB2-NIW Approval for a Chinese PhD Candidate Advancing AI in Drug Development

On May 14^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Artificial Intelligence for Drug Development (Approval Notice).

General Field: Artificial Intelligence for Drug Development

Position at the Time of Case Filing: PhD Candidate

Country of Origin: China

State of Residence at the time of filing: Georgia

Approval Notice Date: May 14^th, 2025

Processing Time: 2 months and 7 days (Premium Processing Requested)

Case Summary:

A highly accomplished PhD candidate from China sought assistance from North America Immigration Law Group (NAILG) for his I-140 EB2-NIW (National Interest Waiver) petition. When he approached our law firm, we immediately recognized the exceptional promise of his research. His groundbreaking work in artificial intelligence applied to drug development required a carefully crafted petition that would demonstrate his extraordinary ability and the national importance of his contributions to the U.S. healthcare system.

The petition was upgraded to premium processing, which led to a swift approval of the client’s I-140 EB2-NIW petition. This showcases the strength of the petition and NAILG’s expert advocacy

Innovative Applications of Artificial Intelligence in Drug Development

Our client’s research focuses on developing advanced AI models and algorithms to improve early disease diagnosis and predict patient responses to new drugs and combination therapies. By enhancing the precision of diagnostics and the effectiveness of treatments, his work aims to accelerate drug discovery and optimize healthcare outcomes, particularly benefiting vulnerable populations such as infants and the elderly.

Key Accomplishments Underscoring Exceptional Ability

The client’s petition presented the following significant achievements:

Authored 5 peer-reviewed journal articles, including 3 first- or co-first-authored papers, and 1 first-authored conference article in prestigious AI and clinical medicine publications, and 2 first-authored preprints
Received 256 citations, highlighting the scholarly influence and ongoing relevance of his work.
Conducted 50+ peer reviews for leading journals and conferences in AI and machine learning, reflecting his recognized expertise.
Secured research support from major funding bodies such as the National Science Foundation (NSF), National Institutes of Health (NIH), and European Research Council (ERC).

Strong Endorsement from Experts

The petition included four recommendation letters, including three independent advisory opinions from leading experts. These letters affirm the pioneering nature and significant impact of his research in AI for drug development. One expert stated:

“In summary, [client] is conducting cutting-edge research into multi-therapy drug development. The high quality of his research is clearly shown by his work reviewing the research of his academic counterparts. [Client’s] research in the artificial intelligence for drug development field is undoubtedly of benefit to both U.S. and global research communities.”

Swift NIW Approval in Just 2 Months and 7 Days

The client’s I-140 EB2-NIW (National Interest Waiver) petition was approved within a remarkable timeframe of 2 months and 7 days with the premium processing, showcasing both the client’s outstanding qualifications and the effectiveness of the petition prepared by NAILG.

We extend our congratulations and eagerly anticipate his continued impact on the field of artificial intelligence in drug development and public health advancements.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.